Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Inclusion Criteria:

• • Male or female at least 18 years of age
• • A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks
• • Serum hs-CRP ≥ 2.0 mg/L
• • A diagnosis of diabetes mellitus OR ASCVD

Exclusion Criteria:

• • Subjects who participated in Part 1 (phase 2b) are not eligible to participate inPart 2 (phase 3)
• • Concomitant use of systemic immunosuppressant drugs
• • Abnormal LFTs
• • Any life-threatening disease expected to result in death within 12 months
• • A history of GI perforation, inflammatory bowel disease (except fully excisedulcerative colitis), or peptic ulcer disease

• -Clinically significant active infection or history of opportunistic or invasivefungal infection